Myriad/Crescendo's rheumatoid arthritis test shows viability in new trial

Myriad Genetics ($MYGN) paid $270 million for Crescendo Bioscience in February and isn't wasting any time promoting the accomplishments of its now wholly owned subsidiary. According to the company, a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity. The trial took place in Sweden involving 235 patients with early-stage rheumatoid arthritis who hadn't taken a prescribed treatment yet. Myriad/Crescendo said the data shows the test's usefulness as helping to determine more personalized treatments. Details are published online in the journal Annals of the Rheumatic Diseases. Release | Abstract

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.